Acadia Healthcare Company Inc (NASDAQ:ACHC) Director Reeve B. Waud sold 150,000 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $38.67, for a total value of $5,800,500.00. Following the sale, the director now owns 10,088 shares in the company, valued at approximately $390,102.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Reeve B. Waud also recently made the following trade(s):
- On Friday, December 15th, Reeve B. Waud sold 100,000 shares of Acadia Healthcare stock. The shares were sold at an average price of $31.80, for a total value of $3,180,000.00.
Shares of Acadia Healthcare Company Inc (NASDAQ ACHC) traded down $0.06 during trading on Wednesday, reaching $41.59. The company had a trading volume of 708,957 shares, compared to its average volume of 1,270,717. Acadia Healthcare Company Inc has a 12 month low of $26.92 and a 12 month high of $54.34. The stock has a market cap of $3,693.90, a PE ratio of 18.16, a price-to-earnings-growth ratio of 1.37 and a beta of 0.69. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.25.
ACHC has been the topic of a number of recent research reports. Wells Fargo & Co initiated coverage on Acadia Healthcare in a research report on Tuesday, January 30th. They issued an “outperform” rating and a $41.00 target price on the stock. Robert W. Baird restated a “hold” rating and issued a $37.00 price objective on shares of Acadia Healthcare in a research report on Friday, December 15th. BidaskClub raised Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research raised Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Monday, February 12th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $45.00 target price (up from $40.00) on shares of Acadia Healthcare in a research note on Friday, February 23rd. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $44.50.
Hedge funds and other institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new stake in shares of Acadia Healthcare during the 4th quarter worth about $150,000. Tyers Asset Management LLC increased its position in Acadia Healthcare by 31.8% during the fourth quarter. Tyers Asset Management LLC now owns 5,904 shares of the company’s stock worth $193,000 after buying an additional 1,424 shares during the period. Xact Kapitalforvaltning AB acquired a new position in Acadia Healthcare during the fourth quarter worth approximately $231,000. CIBC World Markets Inc. acquired a new position in Acadia Healthcare during the fourth quarter worth approximately $236,000. Finally, Arthur Zaske & Associates LLC acquired a new position in Acadia Healthcare during the third quarter worth approximately $283,000.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.